Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET

Company Participants

Jessica Serra – Investor Relations

Mark Foley – Chief Executive Officer

Dustin Sjuts – President

Toby Schilke – Chief Financial Officer

Conference Call Participants

Seamus Fernandez – Guggenheim

Balaji Prasad – Barclays

Chris Shibutani – Goldman Sachs

Stacy Ku – Cowen

David Amsellem – Piper Sandler

Terence Flynn – Morgan Stanley

Operator

Welcome to the Revance Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following managements’ prepared remarks, we will hold a Q&A Session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, May 9, 2023. [Indiscernible]

Jessica Serra

Thank you, operator. Joining us on the call today from Revance are Chief Executive Officer, Mark Foley; President, Dustin Sjuts; and Chief Financial Officer, Toby Schilke.

During this conference call, management will make forward-looking statements, including statements related to 2023 guidance, cash flow breakeven, operating leverage, block buster potential, our ability to draw on our debt and future revenue expenses and forecast our growth potential, [indiscernible] approval and entry into the therapeutics market, our potential in other therapeutics indications, our commercial success, injector and consumer preferences and behavior, the efficacy and duration of DAXXIFY, the benefits to us, practices and consumers of our products and strategy, our customer base, the supply and manufacturing of DAXXIFY, our sales team, our strategic partnerships and our strategy planned operations and commercialization plans and timing.

Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the Company describes in the section titled Risk Factors in our Annual Report on Form 10-K filed with the SEC on February 28, 2023 and our quarterly report on Form 10-Q filed with the SEC today, May 9, 2023.

Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

Also on today’s call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP. A reconciliation of non-GAAP to GAAP measures is included in our earnings release.

With that, I will turn the call over to Mark Foley, Chief Executive Officer of Revance. Mark?